Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitor
Pharma
ASCO: Pfizer one-ups J&J in prostate cancer
Pfizer's Talzenna and Xtandi appears on track for a broader mCSPC label than J&J's PARP doublet Akeega.
Angus Liu
May 30, 2026 8:00am
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
Mar 19, 2026 6:45am
J&J PARP combo Akeega nabs new FDA nod in prostate cancer niche
Dec 15, 2025 12:14pm
FDA advisors unanimously reject Pfizer's Talzenna expansion bid
May 22, 2025 10:20am
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
Apr 24, 2024 8:23am
EU signs off on Merck and AZ's Lynparza after FDA delays ruling
Dec 21, 2022 9:43am
